A panel of experts describes the impact of subcutaneous formulations on oncology workflows and discusses actionable strategies for oncology practice transformation to successfully integrate subcutaneous therapies into clinical workflows.
EP. 1: The Shifting to Subcutaneous Oncology: Recent FDA Approvals
Panelists discuss how the shift from intravenous (IV) to subcutaneous (SubQ) drug administration is transforming oncology care delivery, highlighting its lasting impact on patient experience, health care efficiency, and clinical workflows in light of recent FDA approvals and evolving pharmaceutical strategies.
Watch
EP. 2: Subcutaneous Value: Efficiency and Access
Panelists discuss how subcutaneous (SubQ) drug formulations offer practical value by significantly reducing treatment times, easing staffing pressures, and enhancing efficiency in oncology practices, ultimately supporting a more scalable and sustainable care model.
Watch
EP. 3: Workflow Wins: Scheduling and Pharmacy Impact
Panelists discuss how subcutaneous (SubQ) oncology treatments are reshaping clinic operations by improving infusion chair utilization, enabling flexible scheduling, streamlining pharmacy workflows, and prompting new care delivery models that enhance both efficiency and patient experience.
Watch
EP. 5: Reimbursement Realities: Billing for Subcutaneous
Panelists discuss how incorporating subcutaneous (SubQ) formulations into clinical formularies requires careful evaluation of clinical equivalence, workflow fit, and reimbursement logistics, with pharmacy and therapeutics committees balancing patient benefit, operational feasibility, and financial risk to guide adoption.
Watch
EP. 6: Implementing Subcutaneous Without Disruption
Panelists discuss how successfully integrating subcutaneous (SubQ) therapies into oncology practice depends on comprehensive education, optimized workflows, transparent patient communication, and ongoing evaluation to ensure improved care quality and operational efficiency.
Watch
EP. 7: Operational Shifts: IV to Subcutaneous
Panelists discuss how integrating subcutaneous (SubQ) therapies into oncology practice involves thorough economic evaluation, coordinated team education, patient engagement, and workflow adjustments to ensure financial viability, clinical effectiveness, and enhanced patient satisfaction.
Watch
EP. 8: Staffing and Scheduling for Subcutaneous
Panelists discuss how integrating both intravenous (IV) and subcutaneous (SubQ) therapies in oncology centers requires adaptable staffing, data-driven workflow planning, and thoughtful pilot strategies—combined with strong leadership and patient education—to enhance efficiency, staff engagement, and the overall care experience.
Watch
EP. 9: Patient Selection and Counseling
Panelists discuss how the rise of patient awareness around subcutaneous (SubQ) therapies calls for empathetic, evidence-based education, shared decision-making, and seamless system integration to ensure that treatment choices align with clinical appropriateness, patient preferences, and operational readiness.
Watch
EP. 10: Protocols for Subcutaneous Transitions
Panelists discuss how transitioning patients from intravenous (IV) to subcutaneous (SubQ) therapies demands a coordinated, multidisciplinary approach—integrating clinical judgment, electronic medical record (EMR) readiness, workflow adaptation, and patient-centered communication to ensure safe, efficient, and individualized care.
Watch
EP. 11: Training Nurses for Subcutaneous Delivery
Panelists discuss how switching from intravenous (IV) to subcutaneous (SubQ) therapies requires proactive management of reimbursement, authorizations, and clinical workflows—emphasizing early payer coordination, billing oversight, and nurse retraining to ensure both financial sustainability and safe, efficient patient care.
Watch
EP. 12: Collaborating to Integrate Subcutaneous
Panelists discuss how the rapid adoption of subcutaneous (SubQ) oncology therapies creates challenges around clinical autonomy, infusion center sustainability, patient experience, and reimbursement models, highlighting the need for collaborative education and flexible care strategies to ensure patient-centered, financially viable implementation.
Watch
EP. 13: Overcoming Barriers to Subcutaneous Adoption
Panelists discuss how challenges such as extended nursing workflow, patient hesitancy, limited formulation indications, reimbursement complexities, and insufficient economic incentives slow the broader adoption of subcutaneous (SubQ) oncology therapies, underscoring the need for coordinated stakeholder collaboration and education to drive integration.
Watch
EP. 14: The Future of IV and Subcutaneous Therapies in Oncology
Panelists discuss how subcutaneous (SubQ) and intravenous (IV) oncology therapies will continue to coexist, with patient-specific factors guiding delivery method choices, while ongoing innovation and collaboration drive the growing integration of SubQ formulations as a convenient and adaptable option in cancer care.
Watch